The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III nonsmall cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 5, 2008, Pages 470-475

  Xu, Xiaoqing ^a   Yu, Jinming ^a   Sun, Xindong ^a   Yang, Guoren ^a   Li, Kong ^a   Fu, Zheng ^a   Han, Anqin ^a   Zheng, Jinsong ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Lung neoplasms; Metastasis; Positron emission tomography; Prognosis; Recurrence

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SCINTISCANNING; MALE; METASTASIS; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; CANCER STAGING; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; RADIOGRAPHY; SCINTISCANNING; TUMOR RECURRENCE;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 55249115371     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31816fc943     Document Type: Article

References (18)

1. 18F]fluotodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun. 2002;23:865-870.
2. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol. 2003;21:1285-1292.
3. Jinming Y, Shuanghu Y, Yonghua Y, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med. 2006;47:1255-1259.
4. Guo H, Zhu H, Xi Y, et al. Diagnostic and prognostic value of 18f-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med. 2007;48:1251-1258.
5. Jinming Y, Shuanghu Y, Xue M, et al. Determining optimal clinical target volume margins on the basis of microscopic extracapsular extension of metastatic nodes in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67:727-734.
6. Li WL, Yu JM, Liu GH, et al. A comparative study on radiology and pathology target volume in non-small-cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2003;25:566-568.
7. Borst GR, Belderbos JS, Boellaard S, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41:1533-1541.
8. Rusch V, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup trial 0160). J Thorac Cardiovasc Surg. 2001;121:472-483.
9. Yamamoto Y, Nishiyama Y, Monden T, et al. Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33:140-147.
10. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for rumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357-4368.
11. Pauwels EK, McCready VR, Stoot JH, et al. The mechanism of accumulation of tumor-localizing pharamaceuticals. Eur J Nucl Med. 1998;25:277-305.
12. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med. 2000;41:85-92.
13. Eschmann SM, Friedel G, Paulsen F, et al. Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging. 2006;33:263-269.
14. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med. 1998 Nov;25(11):1495-1501.
15. Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004;78:1903-1909.
16. Pöttgen C, Levegrün S, Theeegarten D, et al. Value of 18F-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res. 2006;12:97-106.
17. Port JL, Kent MS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg. 2004;77:254-259.
18. Dhital K, Saunders CA, Seed PT, et al. 18F fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18:425-428.